Enliven Therapeutics
ELVN
41.36
-1.03
-2.43%
Enliven Therapeutics
US · ELVN
#2416 by market cap
Listed 1970
41.36
-1.03
-2.43%
Live - 5344 symbols - heartbeat 234s ago
· 2026-10-08 08:20
Pre-market
43.00
+3.97%
After-hours
41.36
0.00%
Overnight
41.74
+0.92%
- Market cap
- 3.03B
- P/E (TTM)i
- -25.07
- P/Bi
- 3.39
- EPSi
- -1.83
- Div yieldi
- 0.00%
- 52W posi
- 56%
Reader sentiment
Are you bullish or bearish on ELVN?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Accumulating
- The number of reporting institutions increased by 4 in the most recent period (2026/Q3).
- Total institutional ownership rose 0.3 percentage points.
Institutional ownership
- Held by institutions
- 112.07% +0.32pp
- Institutions
- 250 +4
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund60.48%
Hedge Fund32.86%
VC/PE Fund14.54%
Individual/Insider2.69%
Sovereign Wealth Fund1.89%
Public Company1.40%
Insurance Company0.40%
Government Pension Fund0.29%
Private Company0.16%
Top holders as of 2026-06-30
FMR
13.68% · 10.03M sh
OrbiMed Advisors LLC
9.25% · 6.78M sh
Polar Capital Holdings Plc
8.78% · 6.43M sh
BlackRock
5.95% · 4.36M sh
Vestal Point Capital, LP
5.46% · 4.00M sh
Commodore Capital LP
4.47% · 3.28M sh
T. Rowe Price Group, Inc.
4.37% · 3.20M sh
Vanguard Capital Management, LLC
4.03% · 2.95M sh
Citadel Advisors LLC
2.82% · 2.07M sh
Fairmount Funds Management LLC
2.53% · 1.86M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 15 buys · 35 sells
| Name | Role | Stake |
|---|---|---|
| Joseph Lyssikatos | Co-Founder, Chief Scientific Officer & Directors | 1.01% |
| Samuel Kintz | Co-Founder, CEO, Secretary & Director | 0.89% |
| Anish Patel | Co-Founder & COO | 0.29% |
| Richard Heyman | Independent Chairperson | 0.23% |
| Jacob Bauer | Independent Director | 0.12% |
| Lori Kunkel | Director | 0.06% |
| Helen Collins | Chief Medical Officer | 0.03% |
| Rahul Ballal | Director | 0.03% |
| Benjamin Hohl | CFO & Head of Corporate Development | 0.02% |
| OrbiMed Advisors LLC | -- | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-30 | Scott Garland | Director | Derivative Exercise and Sale | -13,000 | $15.47–46.67 |
| 2026-09-16 | Helen Collins | Chief Medical Officer | Derivative Exercise and Sale | -5,000 | $2.48–51.48 |
| 2026-09-16 | Benjamin Hohl | CFO & Head of Corporate Development | Open Market Disposition | -2,036 | $50.72–51.49 |
| 2026-09-16 | Benjamin Hohl | CFO & Head of Corporate Development | Derivative Exercise and Sale | -3,982 | $14.85–50.72 |
| 2026-09-03 | Richard Heyman | Independent Chairperson | Intent to Sell (Form 144) | -38,000 | $59.29 |
| 2026-08-16 | Helen Collins | Chief Medical Officer | Derivative Exercise and Sale | -5,000 | $2.48–59.35 |
| 2026-08-16 | Benjamin Hohl | CFO & Head of Corporate Development | Automatic Disposition | -6,018 | $58.35–59.35 |
| 2026-08-03 | Mika Derynck | Independent Director | Derivative Exercise and Sale | -158,795 | $2.48–60.21 |
| 2026-07-16 | Helen Collins | Chief Medical Officer | Derivative Exercise and Sale | -5,000 | $2.48–53.92 |
| 2026-07-16 | Benjamin Hohl | CFO & Head of Corporate Development | Automatic Disposition | -4,946 | $52.32–53.87 |
| 2026-07-16 | Benjamin Hohl | CFO & Head of Corporate Development | Derivative Exercise and Sale | -1,072 | $2.48–52.32 |
| 2026-07-05 | Lori Kunkel | Director | Automatic Disposition | -10,000 | $49.98–50.84 |
| 2026-06-21 | OrbiMed Advisors LLC | -- | Private Disposition | -48,253 | $45.00 |
| 2026-06-21 | OrbiMed Advisors LLC | -- | Open Market Disposition | -811,870 | $45.38 |
| 2026-06-16 | Helen Collins | Chief Medical Officer | Derivative Exercise and Sale | -5,000 | $2.48–44.74 |
| 2026-06-16 | Benjamin Hohl | CFO & Head of Corporate Development | Derivative Exercise and Sale | -6,018 | $2.48–44.75 |
| 2026-06-14 | OrbiMed Advisors LLC | -- | Open Market Disposition | -281,408 | $45.02 |
| 2026-06-04 | Lori Kunkel | Director | Automatic Disposition | -10,000 | $34.28–35.82 |
| 2026-05-17 | Helen Collins | Chief Medical Officer | Derivative Exercise and Sale | -5,000 | $2.48–41.21 |
| 2026-04-29 | Joseph Lyssikatos | Co-Founder, Chief Scientific Officer & Directors | Intent to Sell (Form 144) | -25,000 | $42.40 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 08:20:04 · For reference only, not investment advice and not tailored to your situation.